Brief: Chimeric Therapeutics Says Execution Of Clinical Study Agreement With University Of Texas MD Anderson Cancer Center

Chimeric Therapeutics

13/09/2023 02:26

Sept 13 (Reuters) - Chimeric Therapeutics Ltd  CHM.AX :
    * EXECUTION OF A CLINICAL STUDY AGREEMENT WITH UNIVERSITY OF
TEXAS
MD ANDERSON CANCER CENTER
    * STUDY, WHICH HAS RECEIVED IND CLEARANCE BY FDA AND IS
EXPECTED
TO OPEN TO ENROLLMENT AT MD ANDERSON BY YEAR END 2023
    * CLINICAL STUDY AGREEMENT TO SUPPORT "ADVENT-AML" PHASE 1B
STUDY

Source text for Eikon:  ID:nASX3Npqgj 
Further company coverage:  CHM.AX 

 ((Reuters.Briefs@thomsonreuters.com;))